Cytori Therapeutics, Inc. (CYTX): Gail K Naughton , director of Cytori Therapeutics, Inc. purchased 1,000 shares on Jun 14, 2016. The Insider buying transaction was reported by the company on Jun 15, 2016 to the Securities and Exchange Commission. The shares were purchased at $2.10 per share for a total value of $2,100.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 16, 2016, John David Harris (VP and GM Cell Therapy) purchased 2,000 shares at $2.71 per share price.On Mar 9, 2016, David Rickey (director) purchased 150,000 shares at $0.19 per share price.Also, On Sep 8, 2015, Tommy G Thompson (director) purchased 25,449 shares at $0.38 per share price.On Sep 3, 2015, Jeremy B. Hayden (General Counsel & VP of BD) purchased 8,200 shares at $0.35 per share price.
Cytori Therapeutics Inc: On Wednesday, Jun 15, 2016 heightened volatility was witnessed in Cytori Therapeutics Inc which led to swings in the share price. The shares opened for trading at $2.1 and hit $2.28 on the upside , eventually ending the session at $2.16, with a gain of 1.89% or 0.04 points. The heightened volatility saw the trading volume jump to 2,02,662 shares. The 52-week high of the share price is $10.499947 and the company has a market cap of $29 M . The 52-week low of the share price is at $1.91999.
Cytori Therapeutics Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product Cytori Cell Therapy for patients with scleroderma hand dysfunction orthopedic disorders cardiovascular disease urinary incontinence and thermal burns combined with radiation injury. The Company commercializes the Celution System under select medical device approvals clearances and registrations to research customers developing new therapeutic applications for Cytori Cell Therapy in Europe Japan and other regions. The Company offers ECCO-50 a cure for knee osteoarthritis which is in ECCO-50 Phase IIA/B of development. It offers ECCI-50 a cure for urinary incontinence which is in Phase II/III of development. The Company is also developing DCCT-10 a cure for cutaneous thermal injury.